

1 **Phenome-wide Mendelian randomisation analysis identifies causal factors for age-related macular**
2 **degeneration.**

3

4 Thomas H Julian^{1,2}, Johnathan Cooper-Knock³, Stuart MacGregor⁴, Hui Guo⁵, Tariq Aslam^{2,6}, Eleanor
5 Sanderson⁷, Graeme C Black^{1,8}, Panagiotis I Sergouniotis^{1,2,8,9}

6

7 ¹ Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology,
8 Medicine and Health, University of Manchester, Manchester, UK.

9 ² Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

10 ³ Department of Neuroscience, Sheffield Institute for Translational Neuroscience (SITraN), University of
11 Sheffield, Sheffield, UK.

12 ⁴ Statistical Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Australia.

13 ⁵ Centre for Biostatistics, Division of Population Health, Health Services Research and Primary Care,
14 School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester,
15 Manchester, UK.

16 ⁶ Division of Pharmacy and Optometry, Faculty of Biology, Medicine and Health, School of Health
17 Sciences, University of Manchester, Manchester, UK.

18 ⁷ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, United Kingdom.

19 ⁸ Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS
20 Foundation Trust, Manchester, UK.

21 ⁹ European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome
22 Genome Campus, Cambridge, UK.

23

24 **Correspondence to:** Panagiotis Sergouniotis (panagiotis.sergouniotis@manchester.ac.uk) and Graeme
25 Black (graeme.black@manchester.ac.uk)

26

27

28 **IMPACT STATEMENT:**

29 A phenome-wide Mendelian randomisation analysis revealed a causal link between age-related macular
30 degeneration and a number of lipid, complement, immune cell, and serum protein traits, highlighting
31 potential treatment targets.

32

33

34 **ABSTRACT:**

35 **Background:** Age-related macular degeneration (AMD) is a leading cause of blindness in the
36 industrialised world and is projected to affect >280 million people worldwide by 2040. Aiming to identify
37 causal factors and potential therapeutic targets for this common condition, we designed and undertook a
38 phenome-wide Mendelian randomisation (MR) study.

39 **Methods:** We evaluated the effect of 4,591 exposure traits on early AMD using univariable MR.
40 Statistically significant results were explored further using: validation in an advanced AMD cohort; MR
41 Bayesian model averaging (MR-BMA); and multivariable MR.

42 **Results:** Overall, 44 traits were found to be putatively causal for early AMD in univariable analysis.
43 Serum proteins that were found to have significant relationships with AMD included S100-A5 (odds ratio
44 [OR]=1.07, p-value=6.80E-06), cathepsin F (OR=1.10, p-value=7.16E-05) and serine palmitoyltransferase
45 2 (OR=0.86, p-value=1.00E-03). Univariable MR analysis also supported roles for complement and
46 immune cell traits. Although numerous lipid traits were found to be significantly related to AMD, MR-BMA
47 suggested a driving causal role for serum sphingomyelin (marginal inclusion probability [MIP]=0.76;
48 model-averaged causal effect [MACE]=0.29).

49 **Conclusions:** The results of this MR study support several putative causal factors for AMD and highlight
50 avenues for future translational research.

51

52 **Funding:** This project was funded by the Wellcome Trust (224643/Z/21/Z); the University of Manchester's
53 Wellcome Institutional Strategic Support Fund (Wellcome ISSF) grant (204796/Z/16/Z); the UK National
54 Institute for Health Research (NIHR) Academic Clinical Fellow and Clinical Lecturer Programmes; Retina

- 55 UK and Fight for Sight (GR586); the Australian National Health and Medical Research Council (NHMRC)
56 (1150144).

57 **INTRODUCTION**

58
59 Age-related macular degeneration (AMD) is a common retinal condition that affects individuals who are
60 ≥ 50 years old. It is caused by the complex interplay of multiple genetic and environmental risk factors and
61 genome-wide association studies (GWAS) have identified AMD-implicated variants in at least 69 loci.
62 These include important risk alleles in the 1q32 and 10q26 genomic regions (corresponding to the *CFH*
63 [complement factor H] and *ARMS2/HTRA1* locus respectively) (Fritsche et al., 2016; Winkler et al., 2020).
64 Other key risk factors include age, smoking, alcohol consumption and low dietary intake of antioxidants
65 (carotenoids, zinc) (Chakravarthy et al., 2010).

66
67 AMD can be categorised according to severity (early, intermediate, or advanced) or based on the
68 presence of neovascularization (neovascular or non-neovascular). Advanced AMD results in loss of
69 central vision, often leading to severe visual impairment (Fleckenstein et al., 2021). Notably, AMD is a
70 major cause of blindness in the elderly population and represents a substantial global burden that is
71 expected to continue to grow into the future as an ageing population expands worldwide (Chakravarthy et
72 al., 2010).

73
74 Mendelian randomization (MR) is a statistical approach that uses genetic variation to look for causal
75 relationships between *exposures* (such as smoking) and *outcomes* (such as risk of a specific disease)
76 (Julian et al., 2021). MR is increasingly being utilised as it can, to a degree, address a major limitation of
77 observational studies: unmeasured confounding (Sanderson et al., 2022). To minimise issues with certain
78 types of confounding and to support causal inference statements, MR uses genetic variation as an
79 *instrument* (*i.e.* as a variable that is associated with the exposure but is independent of confounders and
80 is not associated with the outcome, other than through the exposure). The principles of MR are based on
81 Mendel's laws of segregation and independent assortment, which state that offspring inherit alleles
82 randomly from their parents and randomly with respect to other locations in the genome. A key concept is
83 the use of genetic variants that are related to an exposure of interest to proxy the part of the exposure
84 that is independent of possible confounding influences (e.g. from the environment or from other traits). It
85 is noted that analogies have been drawn between MR and randomised controlled trials with these two
86 approaches considered proximal in terms of hierarchy of evidence (Julian et al., 2021). To date, the use

87 of MR approaches in the context of AMD has been limited although these methods have been
88 successfully implemented to explore the relationship between AMD and a small number of traits including
89 lipids, thyroid function, CRP and complement factors (Cipriani et al., 2021; Han et al., 2021, 2020b; Li et
90 al., 2022; Zuber et al., 2020).

91 In this study, we developed a systematic, broad ('phenome-wide') MR-based analytical approach and
92 used it to investigate the relationship between early AMD and several thousand exposure variables. A set
93 of traits that are robustly associated with genetic liability to AMD were identified.

94

95 **METHODS**

96

97 **Data sources**

98

99 **Outcome data**

100 Two AMD phenotypes were used as outcome measures in this study. The first one was early AMD. The
101 GWAS summary statistics for this phenotype were taken from a meta-analysis by Winkler and colleagues
102 (Winkler et al., 2020). This meta-analysis focused on populations of European ancestries and used data
103 from the ARIC, AugUR, CHS, GHS, IAMDGC, KORA S4, LIFE-Adult NICOLA, UKBB and WHI studies
104 (14,034 early AMD cases and 91,214 controls overall). A full description of how these studies classified
105 participants as “early AMD” can be found in the relevant publication (Winkler et al., 2020); briefly, a
106 number of approaches considering drusen size/area and the presence or absence of pigmentary
107 abnormalities were utilised including the Three Continent Consortium (3CC) severity scale (Klein et al.,
108 2014), the Rotterdam Eye Study classification (Korb et al. 2014), the Beckman clinical classification
109 (Ferris et al. 2013), and the AREDS-9 step classification scheme (Davis et al. 2005). All relevant studies
110 used colour fundus photography for grading purposes. The second phenotype that we studied was
111 advanced AMD. For this trait, we drew on GWAS summary statistics from a multiple trait analysis of
112 GWAS (MTAG) study by Han and colleagues (Han et al., 2020a). This meta-analysis also focused on
113 individuals with European ancestries and derived data from the IAMDGC 2013 (17,181 cases and 60,074
114 controls) (Fritsche et al., 2013) and IAMDGC 2016 (16,144 advanced AMD cases and 17,832 controls)
115 (Fritsche et al., 2016) studies as well as the GERA study (4,017 cases and 14,984 controls) (Kvale et al.,
116 2015). The relevant summary statistics are primarily reflective of advanced AMD, but the GERA cohort
117 included both advanced and intermediate AMD cases. Advanced AMD was broadly defined by the
118 presence of geographic atrophy or choroidal neovascularisation, although there was a degree of
119 variability in the criteria used in the included studies. Notably, the MTAG approach can leverage the high
120 genetic correlation between the input phenotypes to detect genetic associations relevant only to
121 advanced AMD.

122

123 **Exposure data**

124 A phenome-wide screen was performed to make causal inferences on the role of a wide range of traits in
125 early and advanced AMD. To achieve this, both published and unpublished GWAS data from the IEU
126 open GWAS database were used; these were accessible via the TwoSampleMR programme in R
127 (Hemani et al., 2018). All European GWAS within this database were included with the exception of
128 imaging phenotypes and expression quantitative trait locus (eQTL) related data which were removed. The
129 restriction to European datasets limits the generalisability of the results to other populations but is
130 necessary to produce reliable findings. In the early AMD analysis, studies from the “ukb” and “met-d”
131 batches were excluded as data for these studies were entirely from the UK Biobank resource and, as a
132 result, there was extensive population overlap with the early AMD GWAS (Sudlow et al., 2015). In the
133 advanced AMD analysis, the “ukb” and “met-d” batches were included. The early AMD analysis was
134 conducted on 30/12/2021 and a total of 10,979 traits were considered for analysis. The advanced AMD
135 analysis was conducted on 08/01/2022. On 26/01/2022 we added the newly published “finn-b” (n=2803)
136 traits to the analysis in place of the outdated “finn-a” traits (n=1489). It was impractical to manually inspect
137 the degree of population overlap for all traits prior to conducting the analysis; instead, the degree of
138 overlap for all significant traits was inspected after the analysis.

139

140 **Instrument selection**

141 A statistically driven approach to instrumental variable selection was used. Typically, an arbitrary p-value
142 threshold is set for the identification of appropriate single-nucleotide variants (SNVs); these are
143 subsequently used as instrumental variables (referred to thereafter as *instruments*). A conventional p-
144 value threshold for the selection of instruments is $>5E-08$. This approach however can, in some cases, be
145 problematic. For example, when the number of instruments exceeding this threshold is small, the analysis
146 can be underpowered or, in certain cases of unbiased screens, the results can be inflated (Boddy et al.,
147 2022). With this in mind, the p-value for instrument selection for each trait was set to the level where >5
148 instruments were available for each analysis. More specifically, for each trait, the analysis would first be
149 conducted with a p-value threshold for inclusion of $5E-8$ before sequentially increasing the threshold by a
150 factor of 10 each time until >5 eligible instruments are identified. A predefined maximum p-value of $5E-05$
151 was used and the final range of p-values for inclusion was $5E-06$ to $5E-08$.

152

153

154 **Proxies**

155 Where an exposure instrument was not present in the outcome dataset, a suitable proxy was identified
156 (Hartwig et al., 2016). In the early AMD analysis, this was achieved by using the TwoSampleMR software
157 with a linkage disequilibrium R^2 value of ≥ 0.9 (Purcell et al., 2007). For the advanced AMD phenotype,
158 data that was not derived from the TwoSampleMR resource were used and therefore the Ensembl server
159 was utilised to identify proxies (Cunningham et al., 2022; Hemani et al., 2018).

160

161 **Clumping**

162 SNVs were clumped using a linkage disequilibrium R^2 value of 0.001 and a genetic distance cut-off of
163 10,000 kilo-bases. A European reference panel was used for clumping.

164

165 **Harmonisation**

166 The effects of instruments on outcomes and exposures were harmonised to ensure that the beta values
167 (*i.e.* the regression analysis estimates of effect size) were expressed per additional copy of the same
168 allele (Hartwig et al., 2016). Palindromic alleles (*i.e.* alleles that are the same on the forward as on the
169 reverse strand) with a minor allele frequency (MAF) > 0.42 were omitted from the analysis in order to
170 reduce the risk of errors.

171

172 **Removal of pleiotropic genetic variants and outliers**

173 Pleiotropic instruments and outliers were removed from the analysis by using a statistical approach that
174 removes instruments which are found to be more significant for the outcome than for the exposure
175 (Hemani et al., 2017). Radial MR, a simulation-based approach that detects outlying instruments, was
176 also utilised (Bowden et al., 2018).

177

178 **Causal inference**

179 MR relies on three key assumptions with regards to the instrumental variable: (1) the instrumental SNV
180 should be associated with the exposure; (2) the SNV should not be associated with confounders; (3) the
181 SNV should influence the outcome only through the exposure (Julian et al., 2021).

182
183 MR estimation was primarily performed using a multiplicative random effects (MRE) inverse variance
184 weighted (IVW) method. MRE IVW was selected over a fixed effects (FE) approach as it allows inclusion
185 of heterogeneous instruments (this was certain to occur within the breadth of this screen) (Burgess et al.,
186 2019). A range of “robust measures” were used to increase the accuracy of the results and to account for
187 violations of the above key MR assumptions (Burgess et al., 2019); these measures included weighted
188 median (Bowden et al., 2016a), Egger (Burgess and Thompson, 2017a), weighted mode (Hartwig et al.,
189 2017) and radial MR with modified second order weights (Bowden et al., 2018).

190

191 **Further quality control**

192 The instrument strength was determined using the F-statistic (which tests the association between the
193 instruments and the exposure) (Burgess et al., 2011). F-statistics were calculated against the final set of
194 instruments that were included. A mean F-statistic >10 was considered sufficiently strong.

195

196 The Cochran's Q test was performed for each analysis. Cochran's Q is a measure of heterogeneity
197 among causal estimates and serves as an indicator of the presence of horizontal pleiotropy (which occurs
198 when an instrument exhibits effects on the outcome through pathways other than the exposure) (Bowden
199 and Holmes, 2019). It is noted that a heterogeneous instrument is not necessarily invalid, but rather calls
200 for a primary assessment with an MRE IVW rather than an FE approach; this has been conducted as
201 standard throughout our analysis.

202

203 The MR-Egger intercept test was used to detect horizontal pleiotropy. When this occurs, the Egger
204 regression is robust to horizontal pleiotropy (under the assumption that that pleiotropy is uncorrelated with
205 the association between the SNV and the exposure) (Burgess and Thompson, 2017b). Unless otherwise
206 indicated by the Egger intercept, the assumption that no demonstrable horizontal pleiotropy is present

207 was made and Egger regression was not utilised to determine causal effects (given the low power of this
208 approach in the context of a small number of SNVs) (Bowden et al., 2015).

209
210 The I^2 statistic was calculated as a measure of heterogeneity between variant-specific causal estimates.
211 An $I^2 < 0.9$ indicates that Egger is more likely to be biased towards the null through violation of the 'NO
212 Measurement Error' (NOME) assumption (Bowden et al., 2016b).

213
214 Leave-one-out (LOO) cross-validation was performed for every analysis to determine if any particular
215 SNV was driving the significance of the causal estimates.

216

217 **Management of duplicate traits/GWAS**

218 As the GWAS database that was used contained multiple different GWAS for certain traits, some
219 exposures were analysed on multiple occasions. Where this occurred, the largest sample size study was
220 considered to be the primary analysis. Where there were duplicate studies in the same population, the
221 study with the largest F-statistic was used.

222

223 **Identification of significant results**

224 Before considering an MR result to be significant, the results of a range of causal inference and quality
225 control tests should be taken into account. Notably, it is not necessary for a study to find significance in all
226 measures to determine a true causal relationship. MR is a low power study type and, as such, an overly
227 conservative approach to multiple testing can be excessive (Burgess et al., 2019). However, in the
228 context of the present study the results of the early AMD phenome-wide screen were considered
229 significant only if they remained: significant after false discovery rate correction (FDR) in the MRE IVW;
230 nominally significant in weighted mode and weighted median; and nominally significant throughout the
231 leave-one-out analysis (IVW-MRE) (Benjamini and Hochberg, 1995). This conservative approach was
232 selected as a large number of phenotypes was studied and because we wanted to focus on high
233 confidence signals.

234

235 Where causal traits for early AMD were identified, the relationship between these traits and advanced
236 AMD was studied. These two AMD classifications are phenotypically distinct but are generally part of the

237 same disease spectrum. When traits failed to replicate as causal factors in the advanced AMD dataset it
238 could not be inferred that these traits are not truly causal for early AMD. However, significance in both
239 AMD phenotypes provided support for the detected causal links and evidence that a factor plays a role
240 across the disease spectrum.

241

242 **Multivariable mendelian randomisation**

243 Multivariable MR was performed in circumstances where it was important to estimate the effect of >1
244 closely related (and/or potentially confounding) exposure traits (Sanderson et al., 2019). P-values for the
245 inclusion of instruments for the exposures of interest were optimised to obtain sufficiently high (>10)
246 conditional F-statistics for reliable analysis (Sanderson et al., 2021). With this in mind, selection for
247 exposures began at a p-value threshold of > 5E-08. Where a trait's instruments had a conditional F-
248 statistic <10, the p-value for selection was reduced in an automated manner by factor of 10 until an F-
249 statistic >10 was obtained. The same clumping procedure as in the univariable MR analysis was used.
250 Adjusted Cochran's Q-statistics were calculated, with a p-value of <0.05 indicating significant
251 heterogeneity. Where the Cochran's Q-statistic indicated heterogeneity, a Q-statistic minimisation
252 procedure was used to evaluate the causal relationship; testing assumed both high (0.9) and low (0.1)
253 levels of phenotypic correlation (Sanderson et al., 2021).

254

255 **Two-sample multivariable Mendelian randomisation approach based on Bayesian model** 256 **averaging (MR-BMA)**

257
258 Multivariable MR can be used to obtain effect estimates for a few (potentially related) traits. However, it
259 cannot be directly applied when many traits need to be considered. In contrast, MR-BMA, a Bayesian
260 approach first described by Zuber and colleagues (Zuber et al., 2020), can search over large sets of
261 potential risk factors to determine which are most likely to be causal.

262
263 Notably, Zuber and colleagues previously performed an in-depth analysis which considered the role of
264 lipids against an older AMD GWAS. The relevant study served as proof-of-concept for the MR-BMA
265 method and demonstrated that several lipid traits have causal roles in AMD. However, the analysis had

266 two potential limitations. First, it downweighed fatty acid traits through limiting composite traits for SNV
267 identification to HDL, LDL, and triglycerides. Second, numerous lipid traits with a potential role in AMD
268 were not included in the analysis. For these reasons, we chose to conduct a more comprehensive
269 analysis with a slightly altered approach. The following study design modifications were made compared
270 to the study by Zuber and colleagues (Zuber et al., 2020):

271 (1) Fatty acids were included as a composite trait (utilising GWAS data for serum fatty acids derived from
272 the Nightingale Health 2020 resource as listed in TwoSampleMR package (Hemani et al., 2018)).

273 (2) All lipid and fatty acid measures included in a GWAS by Kettunen and colleagues (Kettunen et al.,
274 2016) were considered as potential causal traits (n=102 traits).

275 (3) A more recent AMD GWAS was used (Winkler et al., 2020).

276 (4) In general, multivariable MR (of any sort) cannot produce reliable results where the studied traits are
277 ≥ 0.99 correlated with respect to the included instruments. For this reason, where two traits were highly
278 correlated, one was removed at random rather than by manually selecting traits in a manner which risks
279 selection bias.

280
281 MR-BMA for immune cell and complement phenotypes was additionally performed. In this analysis,
282 instruments were obtained at genome wide significance ($p\text{-value} > 5E-08$) for every included exposure in
283 the model (given that composite traits were not available/applicable). For the immune cell MR-BMA, all
284 immune traits that were studied in a GWAS by Orru and colleagues (Orrù et al., 2020) and were present
285 in the TwoSampleMR package were used as exposures. In the complement analysis, all complement
286 traits available in relevant studies by Sun and colleagues (Sun et al., 2018) and Suhre and colleagues
287 (Suhre et al., 2017) were used, with the exception of complement subfractions.

288
289 For the MR-BMA analysis, the prior probability was set to 0.1 and the prior variance was set to 0.25. A
290 stochastic search with 10,000 iterations was undertaken and empirical p-values with 100,000
291 permutations were calculated.

292

293 **Presentation of effect sizes:**

294 Effect sizes are presented to enable appraisal of the impact of putative risk factors. For the univariable
295 MR analysis, these are presented as OR per 1 standard deviation (SD) of change in the exposure for
296 continuous traits, and as beta values for binary exposure traits. This approach was selected because
297 ORs are uninformative for binary exposure traits (Burgess and Labrecque, 2018). Furthermore, beta
298 values are not presented by all MR authorities where an exposure variable is binary, and it is often
299 highlighted that these values are only indicative. Multivariable MR effect sizes are presented as beta
300 estimates irrespective of the nature of the exposure variable (given that the role of multivariable MR within
301 this study was purely to identify confounders).

302
303 MR-BMA effect sizes are presented in the form of a model-averaged causal estimate (MACE). The MACE
304 is a conservative estimate of the direct causal effect of an exposure on an outcome averaged across
305 models. It is noted that the primary function of MR-BMA IS to highlight the probable causal trait among a
306 number of candidate causal risk factors. Although the MR-BMA findings can be used to interpret the
307 direction of effect, they should not be necessarily viewed as an absolute guide to magnitude (Zuber et al.,
308 2020).

309

310 **Software**

311 R version 4.1.0.

312 TwoSampleMR version 0.5.6.

313 RadialMR version 1.0.

314 MVMR version 0.3

315 MR-BMA code was sourced from https://github.com/verena-zuber/demo_AMD.

316

317

318 **RESULTS**

319

320 **Overview**

321 Focusing on early AMD, univariable MR analysis was applied to a broad range of traits. Following quality
 322 control, significant results were replicated in an advanced AMD dataset and further analyses were
 323 conducted using multivariable MR and MR-BMA (Zuber et al., 2020).

324

325 Overall, 4,591 traits were eligible for analysis. Among these, 44 were found to be putatively causal for
 326 early AMD (**Table 1 and Table 1 - Source Data 1 & 2**). Most of these causal traits were serum lipoprotein
 327 concentration and compositional measures (n=29). Other significant traits identified included immune cell
 328 phenotypes (n=5), serum proteins (n=6) and disease phenotypes (n=4).

329

Table 1. Significant results detected in a phenome-wide univariable Mendelian randomisation (MR) analysis of early age-related macular degeneration (AMD). Only traits passing the stringent quality control described in the methods are listed.

Trait name	Odds ratio	FDR-adjusted IVW p-value	MRE IVW beta
Rheumatoid arthritis	NA	1.51E-06	0.08
Unswitched memory B cell % B cell	1.11	5.40E-05	0.10
CD62L- Dendritic Cell % dendritic cell	0.95	3.32E-02	-0.05
Effector Memory CD8+ T cell absolute count	1.08	1.79E-04	0.07
CD25 on IgD+ CD38- naive B cell	0.93	1.25E-04	-0.07
CD80 on plasmacytoid dendritic cell	0.96	1.63E-02	-0.04
Total cholesterol in IDL*	0.80	6.48E-08	-0.22
Free cholesterol in IDL*	0.80	5.51E-08	-0.22
Total lipids in IDL*	0.79	3.35E-09	-0.23
Concentration of IDL particles*	0.80	9.83E-09	-0.23
Phospholipids in IDL*	0.79	1.86E-09	-0.23
Triglycerides in IDL*	0.84	2.40E-07	-0.18
Total cholesterol in large LDL*	0.83	9.85E-08	-0.19
Cholesterol esters in large VLDL*	0.83	1.41E-07	-0.19
Free cholesterol in large LDL*	0.83	7.07E-07	-0.18
Total lipids in large LDL*	0.83	1.04E-07	-0.19
Concentration of large LDL particles*	0.83	2.40E-07	-0.19
Phospholipids in large LDL*	0.83	1.33E-06	-0.18

Cholesterol esters in large VLDL*	0.82	6.55E-03	-0.20
18:2 linoleic acid (LA)*	0.80	2.93E-07	-0.23
Total cholesterol in LDL*	0.82	4.46E-08	-0.19
Total cholesterol in medium LDL*	0.82	3.64E-09	-0.20
Cholesterol esters in medium LDL*	0.82	5.93E-09	-0.20
Total lipids in medium LDL*	0.81	3.35E-09	-0.21
Concentration of medium LDL particles*	0.81	3.64E-09	-0.21
Phospholipids in medium LDL*	0.81	1.86E-09	-0.21
Total cholesterol in small LDL*	0.81	9.85E-08	-0.21
Total lipids in small LDL*	0.81	2.65E-07	-0.21
Total cholesterol in small VLDL*	0.85	2.54E-02	-0.16
Serum total cholesterol*	0.77	3.67E-08	-0.26
Total phosphoglycerides*	0.81	3.93E-03	-0.21
Triglycerides in very large HDL*	0.87	4.37E-04	-0.14
Total lipids in very small VLDL*	0.84	1.97E-03	-0.18
Concentration of very small VLDL particles*	0.84	9.04E-04	-0.18
Phospholipids in very small VLDL*	0.83	3.63E-03	-0.19
Interferon alpha-10	1.14	1.83E-02	0.13
Protein S100-A5	1.07	6.94E-04	0.07
Serine palmitoyltransferase 2	0.86	3.17E-02	-0.15
CD59 glycoprotein	1.10	1.77E-03	0.09
Complement factor H-related protein 5	1.09	9.30E-05	0.09
Cathepsin F	1.10	4.44E-03	0.10
Benign neoplasm: Skin, unspecified	NA	8.23E-03	0.07
Psychiatric diseases	NA	8.54E-05	-0.43
Myotonic disorders	NA	2.32E-02	0.00

* these traits (trait ID 'met-c' in **Table 1 - Source Data 1**) had 1.9% sample overlap with the early AMD dataset, a minor degree of overlap which is unlikely to bias results; the remaining causal traits had no sample overlap with early AMD.

FDR, false discovery rate; IVW, inverse variance weighted; MRE, multiplicative random effects; %, as a proportion of; NA, not applicable (as exposure traits of binary nature do not produce accurate odds ratios; beta values can be used instead to infer direction of effect but not necessarily magnitude).

330

331 **Lipoprotein metabolism is linked to AMD risk**

332 Univariable MR demonstrated significant causal relationships for 28 serum lipoprotein measures and 1
 333 serum fatty acid concentration (18:2 linoleic acid) in early AMD (**Table 1**). These relationships were also
 334 strongly supported by the results of our advanced AMD analysis (**Table 1 - Source Data 3**).

335

336 Serum metabolites are highly correlated traits, and the instruments for serum lipoprotein and fatty acid
337 measures in the present study were demonstrably correlated (**Figure 1 - Figure supplement 1**). MR-
338 BMA was used in order to discern which traits were driving the causal relationships. In our initial analysis,
339 two genetic variants (rs11065987 [*BRAP*] and rs10455872 [*LPAL2*]) were found to be outliers in terms of
340 Q-statistic (Q-statistic 13.84-15.71 and 6.79-10.46 respectively across models) (**Figure 1**). These SNVs
341 were therefore omitted and the analysis was re-run. In subsequent analyses, no outlier SNVs were
342 identified. The top 10 models in terms of posterior probability are presented in **Table 1 - Source Data 4**;
343 the top 10 individual risk factors in terms of marginal inclusion probability (MIP; defined as the sum of the
344 posterior probabilities over all the models where the risk factor is present) are shown in **Table 2**. The
345 MIPs of all the traits included this analysis are plotted in **Figure 2**. The top four traits with respect to their
346 MIP were serum sphingomyelins (MIP=0.76, MACE=0.29), triglycerides in IDL (MIP=0.32, MACE=-0.16),
347 free cholesterol (MIP=0.20, MACE=0.07) and phospholipids in very small VLDL (MIP=0.63, MACE= -
348 0.31). It is noted that whilst MR-BMA is designed to select the likely causal risk factor among a set of
349 candidate causal traits, it is often not possible to achieve this with certainty. As such, a definitive
350 statement of causality for individual lipid traits cannot be obtained within the utilised MR causal inference
351 framework.

352
353 Serine palmitoyltransferase 2, an enzyme which catalyses the first committed step in sphingolipid
354 biosynthesis, was robustly associated with early AMD. The detected effect size highlighted that genetic
355 liability to increasing serum enzyme levels is protective of AMD (**Table 1, Table 1 - Source Data 1**; OR
356 0.86, p-value=1.00E-03). It is of interest that increasing serum levels of the related enzyme serine
357 palmitoyltransferase 1 also appeared to be protective of early AMD in most measures (**Table 1 - Source**
358 **Data 2**; OR 0.94, IVW p-value = 2.00E-03, FDR-adjusted IVW p-value = 0.05, weighted median p-value =
359 0.05; significant throughout leave-one-out analysis). Serine palmitoyltransferase enzymes were not
360 significantly related to the risk of advanced AMD (**Table 1 - Source Data 3**).

361

362

363

364

Table 2. Lead causal traits identified by MR-BMA of lipid-related phenotypes in early age-related macular degeneration (AMD) ranked according to their marginal inclusion probability (MIP).

Rank	Risk factor (Trait ID)	Marginal inclusion probability (MIP)	Average effect	Nominal p-value	FDR-adjusted p-value
1	Sphingomyelins (met-c-935)	0.76	0.30	2.40E-04	5.76E-03
2	Phospholipids in very small VLDL (met-c-955)	0.63	-0.31	1.00E-05	7.20E-04
3	Triglycerides in IDL (met-c-872)	0.32	-0.16	2.10E-04	5.76E-03
4	Free cholesterol (met-c-858)	0.20	0.07	2.83E-03	5.09E-02
5	Omega-3 fatty acids (met-c-855)	0.07	0.01	3.70E-02	2.34E-01
6	Free cholesterol in very large HDL (met-c-944)	0.07	0.01	2.74E-02	2.34E-01
7	Total lipids in very small VLDL (met-c-953)	0.06	-0.02	2.08E-02	2.34E-01
8	Cholesterol esters in medium VLDL (met-c-910)	0.05	0.01	3.66E-02	2.34E-01
9	Cholesterol esters in very large HDL (met-c-943)	0.05	0.01	4.87E-02	2.34E-01
10	Ratio of bisallylic groups to double bonds (met-c-844)	0.05	0.01	4.41E-02	2.34E-01

365

366

367 **Reinforcing a causal role for complement**

368 Increasing serum levels of the complement proteins CD59 glycoprotein (OR 1.10, IVW p-value = 2.04E-
369 05) and Complement factor H-related protein 5 (OR 1.10, IVW p-value = 7.70E-07) were found to be
370 associated with genetic liability to early AMD and passed multiple testing correction. Whilst Complement
371 C4, Complement factor B and Complement factor I were also related to early AMD risk at nominal level of
372 significance, they did not exceed the conservative criteria for causal inference imposed in this study with
373 respect to robust measures (**Table 1 - Source Data 2**). In subsequent advanced AMD analyses (**Table 1**
374 **-Source Data 3**), CD59 glycoprotein remained related to disease risk (OR 1.07, IVW p-value = 0.04,
375 weighted median p-value = 9.00E-04, MR-Egger p-value = 2.00E-03, weighted mode p-value = 7.00E-
376 03). Complement factor I reached a nominal level of significance in the IVW measure (OR 0.95, p-value

377 = 0.05) but did not remain significant in robust tests. No other complement measures that were nominally
378 significant for early AMD were found to be significantly related to advanced AMD.

379
380 Complement traits are correlated with one another, and as such MR-BMA analysis was performed. In the
381 initial analysis, the relationship between complement proteins was strongly suggested to be driven by
382 Complement factor H (posterior probability=0.83, MIP=1.00, MACE=-0.68). However, rs2274700
383 (*CFHR3*, Cook's distance 26.26-55.24 and Cochran's Q 0.87-2.12 across models) and rs10824796
384 (*MBL2*, Cook's distance 0.13-9.93 and Cochran's Q 0.87-22.12 across models) were identified as outlier
385 instruments and therefore warranted removal from subsequent analyses. Rs2274700, a genetic variant
386 known to be associated with AMD risk (Liao et al., 2016), represented the only instrument strongly
387 associated with Complement factor H in the MR-BMA analysis and, as such, its removal precluded an
388 informative high-throughput analysis of the complement cascade. Whilst it is clear that there is a causal
389 relationship between complement and AMD, it is not possible to comment with precision about the
390 specific complement-related molecule driving this.

391
392 **Other immune traits have mixed protective and causal effects in AMD**

393 Our screen identified other serum immune traits with potential causal roles in early AMD, with several of
394 these related to dendritic cell populations. These traits were: Unswitched memory B cell as a proportion of
395 B cells (OR=1.11, p-value=4E-07); CD62L- dendritic cell as a proportion of dendritic cells (OR=0.95, p-
396 value=1.22E-03); Effector Memory CD8+ T cell absolute count (OR=0.95, p-value=1.56E-06); CD80 on
397 plasmacytoid dendritic cell (OR=0.96, p-value=4.20E-04); and Interferon alpha 10 (OR=1.14, p-
398 value=5.38E-04). Notably, numerous immune cell traits were also found to be significantly associated with
399 advanced AMD (**Table 1 - Source Data 3**). As with lipids, these traits are highly correlated and it is not
400 possible to confidently pinpoint which immune cell trait is truly causal in a univariable analysis due to
401 potential overlap in terms of genetic instruments. MR-BMA (using data from a GWAS by Orru and
402 colleagues (Orrù et al., 2020)) for the above immune traits was not possible due to the presence of too
403 few genetic variants strongly instrumenting across the exposure variables which, in turn, led to a failure to
404 construct a meaningful model. For this reason, it was not possible to determine which of these specific

405 immune traits are driving the casual relationship between immune cell traits and AMD (though dendritic
406 cell traits dominate the univariable analysis).

407

408 **Disease phenotypes are related to AMD risk**

409 There are four disease phenotypes/groups which were found to be significant at a level which satisfy the
410 criteria for causal inference defined in this study. These traits are rheumatoid arthritis (beta= 0.08, IVW p-
411 value=9.86E-09), psychiatric diseases (beta=-0.43, IVW p-value=6.88E-07), 'benign neoplasm: skin,
412 unspecified' (beta=0.07, IVW p-value= 1.76E-04) and myotonic disorders (beta=-0.003, IVW p-value=
413 7.49E-04). None of these disorders were significant in advanced AMD. The very broad and non-specific
414 definitions encapsulated in the GWAS of benign skin neoplasms, psychiatric disease and myotonic
415 disorder make it challenging to apply further analyses within the scope of this study, but these may be
416 interesting phenotypes for exploration in future studies.

417

418 In univariable MR, rheumatoid arthritis was identified to be causally related to AMD as detailed above.
419 Multivariable MR with effector memory CD8+ T cell absolute count as a second exposure variable
420 (utilising a Q-statistic minimisation procedure) demonstrated that the causal effect of rheumatoid arthritis
421 was either mediated by immune cells or underpinned by correlated pleiotropy (rheumatoid arthritis effect
422 size: 0.03, 95% CI: -0.007 to 0.055; effector memory CD8+ T cell absolute count effect size 0.07, 95% CI:
423 0.001 to 0.19). This finding persists in models assuming both very high (0.9) and low (0.1) phenotypic
424 correlation.

425

426 With respect to the relationship between AMD and psychiatric disease, no reverse causation was
427 identified (p=0.31). More specific psychiatric traits which could be analysed were not significantly related
428 to genetic liability to early AMD (**Table 1 -Source Data 2**). An extensive range of psychiatric disorders
429 were also explored in the advanced AMD dataset and but no significant relationships were detected
430 (**Table 1 - Source Data 3**). Due to the broad nature of this trait, and the negative results for all disorders
431 explored, it was not possible to discern the driving signal behind the significant result for psychiatric
432 disease. It appears probable that psychiatric disease is a false positive result given that it lacks: the

433 supporting evidence of biological plausibility; validation in an advanced AMD dataset; or supportive
434 evidence through significance of other similar traits in the early AMD analysis.

435

436 **Serum cathepsin F and S100 proteins have a causal role in AMD**

437 In addition to the four previously mentioned molecules (**Table 1**, Interferon alpha-10, CD59 glycoprotein,
438 Complement factor H-related protein and serine palmitoyltransferase 2) a further two serum proteins were
439 identified to have likely causal effects. These are S100-A5 (OR 1.07, IVW p-value = 6.80E-06) and
440 Cathepsin F (OR= 1.10, IVW p-value = 7.16E-05).

441

442 Serum cathepsin F was shown to be causally related to early AMD. However, no other molecules from
443 the serum cathepsin group produced significant results for early AMD and no cathepsin group protein was
444 robustly significant for advanced AMD (although cathepsin S and G have significant IVW p-values of
445 1.71E-05 and 0.001 respectively, **Table 1 - Source Data 3**).

446

447 Serum protein S100-A5 was demonstrated to be causal for AMD (OR 1.07, IVW p-value = 6.80E-06).
448 Additionally, protein S100-A13 was significantly related to early AMD risk in both IVW (OR=1.07, p-
449 value=1.22E-05) and robust measures (weighted median p-value=3.31E-05, weighted mode p-
450 value=9.00E-04 , Egger p-value= 1.00E-03) but did not remain significant throughout the leave-one-out
451 analysis, suggesting that the relationship for this particular protein could be driven by a small number of
452 influential variants. Whilst protein S100-A2 was nominally significant in the IVW analysis (p=0.04), it did
453 not pass any robust measures. No S100 group proteins were significantly related to advanced AMD risk
454 (**Table 1 - Source Data 3**).

455

456

457 **DISCUSSION**

458
459 In this study we used MR to advance our understanding of AMD pathogenesis. Our findings indicate
460 protective effects for serum VLDL and IDL compositional and concentration traits in AMD. Causal effects
461 for serum free cholesterol and sphingolipid metabolism were also highlighted. Notably, our results
462 suggest that increasing serum levels of sphingomyelins are causally linked to AMD and we report
463 protective relationships for specific enzymes implicated in sphingolipid biosynthesis. It is known that
464 sphingolipids play key roles in retinal physiology, and there is emerging evidence that some sphingolipids
465 may play a role in AMD pathogenesis (Simon et al., 2021). Further, our findings are in keeping with those
466 of a meta-analysis of metabolomic studies in which pathway enrichment analysis suggested a role for
467 sphingolipid metabolism in AMD (Hou et al., 2020). Whilst sphingomyelin itself has not previously been
468 described as a causative factor for AMD, other substances involved in sphingolipid metabolism (including
469 ceramide, which can serve as both a substrate for sphingomyelin synthesis or a product of sphingomyelin
470 metabolism) have been suggested as causal factors through regulation of retinal cell death, inflammation
471 and neovascularization (Simon et al., 2021). It is known that the balance of sphingolipids has crucial roles
472 in determining cell fates, and, therefore, the contrasting effects of serine palmitoyltransferase and
473 sphingomyelin observed in this study are noteworthy (Taniguchi and Okazaki, 2020). Our study therefore
474 adds weight to the assertion that sphingolipids play a key role in AMD pathophysiology. Further study of
475 sphingolipid metabolism in individuals with AMD is expected to provide important insights and to highlight
476 potential treatment targets.

477
478 Our MR findings support the well-documented assertion that complement plays a key role in AMD
479 pathogenesis (Clark and Bishop, 2018; Jha et al., 2007; Sivaprasad and Chong, 2006). Whilst MR-BMA
480 was not feasible for this set of traits, univariable analysis supported roles for Complement factor H-related
481 protein 5 and CD59 glycoprotein. A causal signal was obtained for Complement factor H-related protein
482 5, a finding in keeping with recent studies highlighting the role of this and other factor-H-related proteins
483 (FHR-1 to FHR4; all involved in the regulation of complement factor C3b turnover) in AMD (Cipriani et al.,
484 2021). An intriguing observation was the apparently causal role of increasing serum levels of the
485 complement-related CD59 glycoprotein (an inhibitor of membrane attack complex formation) in both early

486 and advanced AMD. This finding appears to be at odds with previous studies that investigated the impact
487 of high levels of CD59 in a model of AMD and found a potential therapeutic benefit (Cashman et al.,
488 2011). The relationship between systemic and local complement activation is poorly understood and
489 studies have produced conflicting results with respect to the roles of each complement molecule in AMD
490 (Clark and Bishop, 2018; Jha et al., 2007). It can therefore be speculated that the superficially
491 inconsistent results between our study and previous reports on CD59 reflect the complicated relationship
492 between serum and retinal CD59 expression.

493
494 Notably, a connection between complement and lipid accumulation has been proposed in AMD. This is
495 due to the observation that dysregulation of the complement system results in lipid deposition both
496 systemically and in the retina. There is also metabolomic evidence that decreased VLDL and increased
497 HDL levels are associated with increased complement activation independent of AMD status (Armento et
498 al., 2021). Given our results, the relationship between VLDL and complement is an area warranting
499 further study.

500
501 Cathepsins are a very diverse family of lysosomal proteases which play an important part in cellular
502 homeostasis by participating in antigen processing and by degrading chemokines and proteases (Yadati
503 et al., 2020). Cathepsins are susceptible to age-related alterations and have been linked to modulation of
504 pro-inflammatory signalling pathways. Additionally, cathepsins D and S play a direct role in the retina as
505 they help with the degradation of photoreceptor outer segments. It has also been shown that
506 homozygosity for variant B cystatin C (an inhibitor of cysteine proteases) causes reduced secretion of
507 mature cystatin C and is associated with increased susceptibility to neovascular AMD (Turk et al., 2012;
508 Zurdel et al., 2002). For these reasons, it has been suggested that dysregulation of cathepsin activity may
509 be a factor in AMD pathophysiology. Here, we show data suggesting that serum cathepsin F, a
510 ubiquitously expressed cysteine cathepsin, has a causal relationship with early AMD. The roles of specific
511 cathepsins in AMD is an area that has not yet been mechanistically explored.

512
513 S100 proteins act as intracellular regulators and extracellular signalling proteins. Intracellularly, S100
514 proteins have a wide range of roles including regulating proliferation, differentiation, apoptosis, calcium
515 homeostasis, metabolism, and inflammation (Donato et al., 2013). Extracellular S100 proteins have

516 important roles in immunity and inflammation. Of the S100 protein family, serum S100-A5 is the only
517 protein to be robustly identified as a causal factor for AMD in our study. Whilst S100 proteins have
518 received little study in AMD thus far, the binding of S100B to RAGE (Receptor for Advanced Glycation
519 End products) and the subsequent increase in VEGF have previously been shown to be linked to the
520 development of AMD (Ma et al., 2007; Xia et al., 2017). S100-A5 is a protein which has received little
521 study and, as such, its biological functions are mostly uncharacterised, (although is known to be involved
522 in inflammation via the activation of RAGE) (Wheeler and Harms, 2017). Whilst it is outside the scope of
523 this study to assert a mechanistic hypothesis for this finding, it seems likely that S100-A5 could be linked
524 to inflammatory processes.

525
526 To a large extent, the present study has captured known AMD risk factors. A notable omission however is
527 smoking, an accepted AMD contributor. In this study, cigarettes smoked per day was associated with
528 early AMD at a nominal level of significance (IVW p-value = 0.009) but was not significant with FDR
529 adjustment or in other measures. This finding is most probably reflective of the underpowered nature of
530 MR. Given the hypothesis-free design of this study and the low power of MR, it would be inappropriate to
531 conclude that non-significant results provide evidence of no relationship between certain environmental
532 exposures and AMD.

533
534 In summary, this study has identified previously undescribed causal factors for AMD in addition to
535 reinforcing several previously suggested AMD risk factors. Future research will: explore how the
536 interaction between causal traits affects AMD risk; investigate how the casual and protective factors
537 described here alter the progression of established disease; and follow-up these causal factors from a
538 mechanistic perspective in order to open up avenues for therapeutic interventions.

539

540 **Ethical approval**

541 This study utilised publicly available data and no additional ethical approval is required.

542

543 **ACKNOWLEDGEMENTS**

544 We acknowledge funding from the Wellcome Trust (224643/Z/21/Z); the University of Manchester's
545 Wellcome Institutional Strategic Support Fund (Wellcome ISSF) grant (204796/Z/16/Z); the UK National
546 Institute for Health Research (NIHR) Academic Clinical Fellow and Clinical Lecturer Programmes; Retina
547 UK and Fight for Sight (GR586); the Australian National Health and Medical Research Council (NHMRC)
548 (1150144).

549

550

551 **COMPETING INTERESTS**

552 TA is involved on advisory boards and has received grants and speaker fees from Allergan, Novartis,
553 Bayer, Roche, Bausch and Lomb, Heidelberg, Topcon and Canon. The remaining authors declare no
554 competing interests.

555

556 **DATA AVAILABILITY**

557 All data associated with this study are provided within the supplementary data.

558

559 **REFERENCES**

- 560 Armento A, Ueffing M, Clark SJ. 2021. The complement system in age-related macular degeneration. *Cell*
561 *Mol Life Sci* **78**:4487–4505.
- 562 Benjamini Y, Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to
563 multiple testing. *J R Stat Soc* **57**:289–300.
- 564 Boddy S, Islam M, Moll T, Kurz J, Burrows D, McGown A, Bhargava A, Julian TH, Harvey C, Marshall
565 JNG, Hall BPC, Allen SP, Kenna KP, Sanderson E, Zhang S, Ramesh T, Snyder MP, Shaw PJ,
566 McDermott C, Cooper-Knock J. 2022. Unbiased metabolome screen leads to personalized medicine
567 strategy for amyotrophic lateral sclerosis. *Brain Commun* **4**. doi:10.1093/braincomms/fcac069
- 568 Bowden J, Davey Smith G, Burgess S. 2015. Mendelian randomization with invalid instruments: effect
569 estimation and bias detection through Egger regression. *Int J Epidemiol* **44**:512–525.
- 570 Bowden J, Davey Smith G, Haycock PC, Burgess S. 2016a. Consistent Estimation in Mendelian
571 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol*
572 **40**:304–314.
- 573 Bowden J, Del Greco M. F, Minelli C, Smith GD, Sheehan NA, Thompson JR. 2016b. Assessing the
574 suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger
575 regression: the role of the I² statistic. *International Journal of Epidemiology*. doi:10.1093/ije/dyw220
- 576 Bowden J, Holmes MV. 2019. Meta-analysis and Mendelian randomization: A review. *Res Synth Methods*
577 **10**:486–496.
- 578 Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C, Davey Smith G. 2018.
579 Improving the visualization, interpretation and analysis of two-sample summary data Mendelian
580 randomization via the Radial plot and Radial regression. *Int J Epidemiol* **47**:1264–1278.
- 581 Burgess S, Labrecque JA. 2018. Mendelian randomization with a binary exposure variable: interpretation
582 and presentation of causal estimates. *European Journal of Epidemiology*. doi:10.1007/s10654-018-

- 583 0424-6
584 Burgess S, Smith GD, Davies NM, Dudbridge F, Gill D, Maria Glymour M, Hartwig FP, Holmes MV,
585 Minelli C, Relton CL, Theodoratou E. 2019. Guidelines for performing Mendelian randomization
586 investigations. *Wellcome Open Research* **4**. doi:10.12688/wellcomeopenres.15555.2
587 Burgess S, Thompson SG. 2017a. Interpreting findings from Mendelian randomization using the MR-
588 Egger method. *Eur J Epidemiol* **32**:377–389.
589 Burgess S, Thompson SG. 2017b. Erratum to: Interpreting findings from Mendelian randomization using
590 the MR-Egger method. *Eur J Epidemiol* **32**:391–392.
591 Burgess S, Thompson SG, CRP CHD Genetics Collaboration. 2011. Avoiding bias from weak instruments
592 in Mendelian randomization studies. *Int J Epidemiol* **40**:755–764.
593 Cashman SM, Ramo K, Kumar-Singh R. 2011. A Non Membrane-Targeted Human Soluble CD59
594 Attenuates Choroidal Neovascularization in a Model of Age Related Macular Degeneration. *PLoS*
595 *ONE*. doi:10.1371/journal.pone.0019078
596 Chakravarthy U, Wong TY, Fletcher A, Piau E, Evans C, Zlateva G, Buggage R, Pleil A, Mitchell P.
597 2010. Clinical risk factors for age-related macular degeneration: a systematic review and meta-
598 analysis. *BMC Ophthalmology*. doi:10.1186/1471-2415-10-31
599 Cipriani V, Tierney A, Griffiths JR, Zuber V, Sergouniotis PI, Yates JRW, Moore AT, Bishop PN, Clark SJ,
600 Unwin RD. 2021. Beyond factor H: The impact of genetic-risk variants for age-related macular
601 degeneration on circulating factor-H-like 1 and factor-H-related protein concentrations. *Am J Hum*
602 *Genet* **108**:1385–1400.
603 Clark SJ, Bishop PN. 2018. The eye as a complement dysregulation hotspot. *Semin Immunopathol*
604 **40**:65–74.
605 Cunningham F, Allen JE, Allen J, Alvarez-Jarreta J, Amode MR, Armean IM, Austine-Orimoloye O, Azov
606 AG, Barnes I, Bennett R, Berry A, Bhai J, Bignell A, Billis K, Boddu S, Brooks L, Charkhchi M,
607 Cummins C, Da Rin Fioretto L, Davidson C, Dodiya K, Donaldson S, El Houdaigui B, El Naboulsi T,
608 Fatima R, Giron CG, Genev T, Martinez JG, Guijarro-Clarke C, Gymer A, Hardy M, Hollis Z, Hourlier
609 T, Hunt T, Juettemann T, Kaikala V, Kay M, Lavidas I, Le T, Lemos D, Marugán JC, Mohanan S,
610 Mushtaq A, Naven M, Ogeh DN, Parker A, Parton A, Perry M, Piližota I, Prosovetskaia I, Sakthivel
611 MP, Salam AIA, Schmitt BM, Schuilenburg H, Sheppard D, Pérez-Silva JG, Stark W, Steed E,
612 Sutinen K, Sukumaran R, Sumathipala D, Suner M-M, Szpak M, Thormann A, Tricomi FF, Urbina-
613 Gómez D, Veidenberg A, Walsh TA, Walts B, Willhoft N, Winterbottom A, Wass E, Chakiachvili M,
614 Flint B, Frankish A, Giorgetti S, Haggerty L, Hunt SE, Ilesley GR, Loveland JE, Martin FJ, Moore B,
615 Mudge JM, Muffato M, Perry E, Ruffier M, Tate J, Thybert D, Trevanion SJ, Dyer S, Harrison PW,
616 Howe KL, Yates AD, Zerbino DR, Flicek P. 2022. Ensembl 2022. *Nucleic Acids Res* **50**:D988–D995.
617 Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. 2013. Functions of S100 proteins.
618 *Curr Mol Med* **13**:24–57.
619 Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong
620 WT, Chew EY. 2021. Age-related macular degeneration. *Nat Rev Dis Primers* **7**:31.
621 Fritsche LG, Chen W, Schu M, Yaspan BL, Yu Y, Thorleifsson G, Zack DJ, Arakawa S, Cipriani V, Ripke
622 S, Igo RP Jr, Buitendijk GHS, Sim X, Weeks DE, Guymer RH, Merriam JE, Francis PJ, Hannum G,
623 Agarwal A, Ambrecht AM, Audo I, Aung T, Barile GR, Benhaboune M, Bird AC, Bishop PN,
624 Branham KE, Brooks M, Brucker AJ, Cade WH, Cain MS, Campochiaro PA, Chan C-C, Cheng C-Y,
625 Chew EY, Chin KA, Chowers I, Clayton DG, Cojocaru R, Conley YP, Cornes BK, Daly MJ, Dhillon B,
626 Edwards AO, Evangelou E, Fagerness J, Ferreyra HA, Friedman JS, Geirsdottir A, George RJ,
627 Gieger C, Gupta N, Hagstrom SA, Harding SP, Haritoglou C, Heckenlively JR, Holz FG, Hughes G,
628 Ioannidis JPA, Ishibashi T, Joseph P, Jun G, Kamatani Y, Katsanis N, Keilhauer C, Khan JC, Kim
629 IK, Kiyohara Y, Klein BEK, Klein R, Kovach JL, Kozak I, Lee CJ, Lee KE, Lichtner P, Lotery AJ,
630 Meitinger T, Mitchell P, Mohand-Saïd S, Moore AT, Morgan DJ, Morrison MA, Myers CE, Naj AC,
631 Nakamura Y, Okada Y, Orlin A, Ortube MC, Othman MI, Pappas C, Park KH, Pauer GJT, Peachey
632 NS, Poch O, Priya RR, Reynolds R, Richardson AJ, Ripp R, Rudolph G, Ryu E, Sahel J-A,
633 Schaumberg DA, Scholl HPN, Schwartz SG, Scott WK, Shahid H, Sigurdsson H, Silvestri G,
634 Sivakumaran TA, Smith RT, Sobrin L, Souied EH, Stambolian DE, Stefansson H, Sturgill-Short GM,
635 Takahashi A, Tosakulwong N, Truitt BJ, Tsironi EE, Uitterlinden AG, van Duijn CM, Vijaya L,
636 Vingerling JR, Vithana EN, Webster AR, Wichmann H-E, Winkler TW, Wong TY, Wright AF, Zelenika
637 D, Zhang M, Zhao L, Zhang K, Klein ML, Hageman GS, Lathrop GM, Stefansson K, Allikmets R,
638 Baird PN, Gorin MB, Wang JJ, Klaver CCW, Seddon JM, Pericak-Vance MA, Iyengar SK, Yates

- 639 JRW, Swaroop A, Weber BHF, Kubo M, Deangelis MM, Léveillard T, Thorsteinsdottir U, Haines JL,
640 Farrer LA, Heid IM, Abecasis GR, AMD Gene Consortium. 2013. Seven new loci associated with
641 age-related macular degeneration. *Nat Genet* **45**:433–9, 439e1–2.
- 642 Fritsche LG, Igl W, Bailey JNC, Grassmann F, Sengupta S, Bragg-Gresham JL, Burdon KP, Hebbbring SJ,
643 Wen C, Gorski M, Kim IK, Cho D, Zack D, Souied E, Scholl HPN, Bala E, Lee KE, Hunter DJ, Sardell
644 RJ, Mitchell P, Merriam JE, Cipriani V, Hoffman JD, Schick T, Lechanteur YTE, Guymer RH,
645 Johnson MP, Jiang Y, Stanton CM, Buitendijk GHS, Zhan X, Kwong AM, Boleda A, Brooks M, Gieser
646 L, Ratnapriya R, Branham KE, Foerster JR, Heckenlively JR, Othman MI, Vote BJ, Liang HH,
647 Souzeau E, McAllister IL, Isaacs T, Hall J, Lake S, Mackey DA, Constable IJ, Craig JE, Kitchner TE,
648 Yang Z, Su Z, Luo H, Chen D, Ouyang H, Flagg K, Lin D, Mao G, Ferreyra H, Stark K, von Strachwitz
649 CN, Wolf A, Brandl C, Rudolph G, Olden M, Morrison MA, Morgan DJ, Schu M, Ahn J, Silvestri G,
650 Tsironi EE, Park KH, Farrer LA, Orlin A, Brucker A, Li M, Curcio CA, Mohand-Saïd S, Sahel J-A,
651 Audo I, Benchaboune M, Cree AJ, Rennie CA, Goverdhan SV, Grunin M, Hagbi-Levi S,
652 Campochiaro P, Katsanis N, Holz FG, Blond F, Blanché H, Deleuze J-F, Igo RP Jr, Truitt B, Peachey
653 NS, Meuer SM, Myers CE, Moore EL, Klein R, Hauser MA, Postel EA, Courtenay MD, Schwartz SG,
654 Kovach JL, Scott WK, Liew G, Tan AG, Gopinath B, Merriam JC, Smith RT, Khan JC, Shahid H,
655 Moore AT, McGrath JA, Laux R, Brantley MA Jr, Agarwal A, Ersoy L, Caramoy A, Langmann T,
656 Saksens NTM, de Jong EK, Hoyng CB, Cain MS, Richardson AJ, Martin TM, Blangero J, Weeks DE,
657 Dhillon B, van Duijn CM, Doheny KF, Romm J, Klaver CCW, Hayward C, Gorin MB, Klein ML, Baird
658 PN, den Hollander AI, Fauser S, Yates JRW, Allikmets R, Wang JJ, Schaumberg DA, Klein BEK,
659 Hagstrom SA, Chowers I, Lotery AJ, Léveillard T, Zhang K, Brilliant MH, Hewitt AW, Swaroop A,
660 Chew EY, Pericak-Vance MA, DeAngelis M, Stambolian D, Haines JL, Iyengar SK, Weber BHF,
661 Abecasis GR, Heid IM. 2016. A large genome-wide association study of age-related macular
662 degeneration highlights contributions of rare and common variants. *Nat Genet* **48**:134–143.
- 663 Han X, Gharahkhani P, Mitchell P, Liew G, Hewitt AW, MacGregor S. 2020a. Genome-wide meta-
664 analysis identifies novel loci associated with age-related macular degeneration. *J Hum Genet*
665 **65**:657–665.
- 666 Han X, Ong J-S, An J, Hewitt AW, Gharahkhani P, MacGregor S. 2020b. Using Mendelian randomization
667 to evaluate the causal relationship between serum C-reactive protein levels and age-related macular
668 degeneration. *Eur J Epidemiol* **35**:139–146.
- 669 Han X, Ong J-S, Hewitt AW, Gharahkhani P, MacGregor S. 2021. The effects of eight serum lipid
670 biomarkers on age-related macular degeneration risk: a Mendelian randomization study. *Int J*
671 *Epidemiol* **50**:325–336.
- 672 Hartwig FP, Davey Smith G, Bowden J. 2017. Robust inference in summary data Mendelian
673 randomization via the zero modal pleiotropy assumption. *Int J Epidemiol* **46**:1985–1998.
- 674 Hartwig FP, Davies NM, Hemani G, Davey Smith G. 2016. Two-sample Mendelian randomization:
675 avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *Int J*
676 *Epidemiol* **45**:1717–1726.
- 677 Hemani G, Tilling K, Davey Smith G. 2017. Orienting the causal relationship between imprecisely
678 measured traits using GWAS summary data. *PLoS Genet* **13**:e1007081.
- 679 Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J,
680 Langdon R, Tan VY, Yarmolinsky J, Shihab HA, Timpson NJ, Evans DM, Relton C, Martin RM,
681 Davey Smith G, Gaunt TR, Haycock PC. 2018. The MR-Base platform supports systematic causal
682 inference across the human phenome. *Elife* **7**. doi:10.7554/eLife.34408
- 683 Hou X-W, Wang Y, Pan C-W. 2020. Metabolomics in Age-Related Macular Degeneration: A Systematic
684 Review. *Invest Ophthalmol Vis Sci* **61**:13.
- 685 Jha P, Bora PS, Bora NS. 2007. The role of complement system in ocular diseases including uveitis and
686 macular degeneration. *Mol Immunol* **44**:3901–3908.
- 687 Julian TH, Boddy S, Islam M, Kurz J, Whittaker KJ, Moll T, Harvey C, Zhang S, Snyder MP, McDermott C,
688 Cooper-Knock J, Shaw PJ. 2021. A review of Mendelian randomization in amyotrophic lateral
689 sclerosis. *Brain*. doi:10.1093/brain/awab420
- 690 Kettunen J, Demirkan A, Würtz P, Draisma HHM, Haller T, Rawal R, Vaarhorst A, Kangas AJ, Lyytikäinen
691 L-P, Pirinen M, Pool R, Sarin A-P, Soininen P, Tukiainen T, Wang Q, Tiainen M, Tynkkynen T, Amin
692 N, Zeller T, Beekman M, Deelen J, van Dijk KW, Esko T, Hottenga J-J, van Leeuwen EM, Lehtimäki
693 T, Mihailov E, Rose RJ, de Craen AJM, Gieger C, Kähönen M, Perola M, Blankenberg S, Savolainen
694 MJ, Verhoeven A, Viikari J, Willemsen G, Boomsma DI, van Duijn CM, Eriksson J, Jula A, Järvelin M-

- 695 R, Kaprio J, Metspalu A, Raitakari O, Salomaa V, Slagboom PE, Waldenberger M, Ripatti S, Ala-
696 Korpela M. 2016. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel
697 systemic effects of LPA. *Nat Commun* **7**:11122.
- 698 Klein R, Meuer SM, Myers CE, Buitendijk GHS, Rohtchina E, Choudhury F, de Jong PTVM, McKean-
699 Cowdin R, Iyengar SK, Gao X, Lee KE, Vingerling JR, Mitchell P, Klaver CCW, Wang JJ, Klein BEK.
700 2014. Harmonizing the classification of age-related macular degeneration in the three-continent AMD
701 consortium. *Ophthalmic Epidemiol* **21**:14–23.
- 702 Kvale MN, Hesselton S, Hoffmann TJ, Cao Y, Chan D, Connell S, Croen LA, Dispensa BP, Eshragh J,
703 Finn A, Gollub J, Iribarren C, Jorgenson E, Kushi LH, Lao R, Lu Y, Ludwig D, Mathauda GK, McGuire
704 WB, Mei G, Miles S, Mittman M, Patil M, Quesenberry CP Jr, Ranatunga D, Rowell S, Sadler M,
705 Sakoda LC, Shapero M, Shen L, Shenoy T, Smethurst D, Somkin CP, Van Den Eeden SK, Walter L,
706 Wan E, Webster T, Whitmer RA, Wong S, Zau C, Zhan Y, Schaefer C, Kwok P-Y, Risch N. 2015.
707 Genotyping Informatics and Quality Control for 100,000 Subjects in the Genetic Epidemiology
708 Research on Adult Health and Aging (GERA) Cohort. *Genetics* **200**:1051–1060.
- 709 Liao X, Lan C-J, Cheuk I-W-Y, Tan Q-Q. 2016. Four complement factor H gene polymorphisms in
710 association with AMD: A meta-analysis. *Arch Gerontol Geriatr* **64**:123–129.
- 711 Li X, Li H, Cheng J, Wang M, Zhong Y, Shi G, Yu A-Y. 2022. Causal Associations of Thyroid Function
712 and Age-Related Macular Degeneration: A Two-Sample Mendelian Randomization Study. *Am J*
713 *Ophthalmol* **239**:108–114.
- 714 Ma W, Lee SE, Guo J, Qu W, Hudson BI, Schmidt AM, Barile GR. 2007. RAGE ligand upregulation of
715 VEGF secretion in ARPE-19 cells. *Invest Ophthalmol Vis Sci* **48**:1355–1361.
- 716 Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, Sole G, Lai S, Dei M, Mulas A, Viridis F, Piras
717 MG, Lobina M, Marongiu M, Pitzalis M, Deidda F, Loizedda A, Onano S, Zoledziewska M, Sawcer S,
718 Devoto M, Gorospe M, Abecasis GR, Floris M, Pala M, Schlessinger D, Fiorillo E, Cucca F. 2020.
719 Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. *Nat Genet*
720 **52**:1036–1045.
- 721 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, Maller J, Sklar P, de Bakker PIW,
722 Daly MJ, Sham PC. 2007. PLINK: a tool set for whole-genome association and population-based
723 linkage analyses. *Am J Hum Genet* **81**:559–575.
- 724 Sanderson E, Davey Smith G, Windmeijer F, Bowden J. 2019. An examination of multivariable Mendelian
725 randomization in the single-sample and two-sample summary data settings. *Int J Epidemiol* **48**:713–
726 727.
- 727 Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, Palmer T, Schooling CM,
728 Wallace C, Zhao Q, Davey Smith G. 2022. Mendelian randomization. *Nat Rev Methods Primers* **2**.
729 doi:10.1038/s43586-021-00092-5
- 730 Sanderson E, Spiller W, Bowden J. 2021. Testing and correcting for weak and pleiotropic instruments in
731 two-sample multivariable Mendelian randomization. *Stat Med* **40**:5434–5452.
- 732 Simon MV, Basu SK, Qaladize B, Gramberg R, Rotstein NP, Mandal N. 2021. Sphingolipids as critical
733 players in retinal physiology and pathology. *J Lipid Res* **62**:100037.
- 734 Sivaprasad S, Chong NV. 2006. The complement system and age-related macular degeneration. *Eye*
735 **20**:867–872.
- 736 Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J, Landray M,
737 Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T, Collins R. 2015. UK
738 biobank: an open access resource for identifying the causes of a wide range of complex diseases of
739 middle and old age. *PLoS Med* **12**:e1001779.
- 740 Suhre K, Arnold M, Bhagwat AM, Cotton RJ, Engelke R, Raffler J, Sarwath H, Thareja G, Wahl A, DeLisle
741 RK, Gold L, Pezer M, Lauc G, El-Din Selim MA, Mook-Kanamori DO, Al-Dous EK, Mohamoud YA,
742 Malek J, Strauch K, Grallert H, Peters A, Kastenmüller G, Gieger C, Graumann J. 2017. Connecting
743 genetic risk to disease end points through the human blood plasma proteome. *Nat Commun*
744 **8**:14357.
- 745 Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, Burgess S, Jiang T, Paige E,
746 Surendran P, Oliver-Williams C, Kamat MA, Prins BP, Wilcox SK, Zimmerman ES, Chi A, Bansal N,
747 Spain SL, Wood AM, Morrell NW, Bradley JR, Janjic N, Roberts DJ, Ouwehand WH, Todd JA,
748 Soranzo N, Suhre K, Paul DS, Fox CS, Plenge RM, Danesh J, Runz H, Butterworth AS. 2018.
749 Genomic atlas of the human plasma proteome. *Nature* **558**:73–79.
- 750 Taniguchi M, Okazaki T. 2020. Ceramide/sphingomyelin rheostat regulated by sphingomyelin synthases

751 and chronic diseases in Murine models. *J Lipid Atheroscler* **9**:380–405.
752 Turk V, Stoka V, Vasiljeva O, Renko M, Sun T, Turk B, Turk D. 2012. Cysteine cathepsins: from structure,
753 function and regulation to new frontiers. *Biochim Biophys Acta* **1824**:68–88.
754 Wheeler LC, Harms MJ. 2017. Human S100A5 binds Ca²⁺ and Cu²⁺ independently. *BMC Biophys* **10**:8.
755 Winkler TW, Grassmann F, Brandl C, Kiel C, Günther F, Strunz T, Weidner L, Zimmermann ME, Korb CA,
756 Poplawski A, Schuster AK, Müller-Nurasyid M, Peters A, Rauscher FG, Elze T, Horn K, Scholz M,
757 Cañadas-Garre M, McKnight AJ, Quinn N, Hogg RE, Küchenhoff H, Heid IM, Stark KJ, Weber BHF.
758 2020. Genome-wide association meta-analysis for early age-related macular degeneration highlights
759 novel loci and insights for advanced disease. *BMC Med Genomics* **13**:120.
760 Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X. 2017. S100 Proteins As an Important Regulator of
761 Macrophage Inflammation. *Front Immunol* **8**:1908.
762 Yadati T, Houben T, Bitorina A, Shiri-Sverdlov R. 2020. The Ins and Outs of Cathepsins: Physiological
763 Function and Role in Disease Management. *Cells* **9**. doi:10.3390/cells9071679
764 Zuber V, Colijn JM, Klaver C, Burgess S. 2020. Selecting likely causal risk factors from high-throughput
765 experiments using multivariable Mendelian randomization. *Nat Commun* **11**:29.
766 Zurdel J, Finckh U, Menzer G, Nitsch RM, Richard G. 2002. CST3 genotype associated with exudative
767 age related macular degeneration. *Br J Ophthalmol* **86**:214–219.

768

769

770

771

772 **FIGURE LEGENDS**

773

774 **Figure 1:** Plots outlining the top-ranking models with respect to their posterior probability in the first run of
775 Mendelian randomisation Bayesian model averaging (MR-BMA) of lipid-related traits in early age-related
776 macular degeneration (AMD). Plots 1A and 1C present Cook's distance while plots 1B and 1D present
777 Cochran's Q. Outlier instruments are annotated.

778

779 The Cochran's Q is a measure which serves to identify outlier variants with respect to the fit of the linear
780 model. The Q statistic is used to identify heterogeneity in a meta-analysis, and to pinpoint specific
781 variants as outliers. The contribution of variants to the overall Q statistic is measured (defined as the
782 weighted squared difference between the observed and predicted association with the outcome) in order
783 to identify outliers. Cook's distance on the other hand is utilised to identify influential observations (*i.e.*
784 those variants which have a strong association with the outcome). Such variants are removed from the
785 analysis because they may have an undue influence over variable selection, leading to models which fit
786 that variant well but others poorly.

787

788 **Figure 2:** Graph detailing the results of a Mendelian randomisation Bayesian model averaging (MR-BMA)
789 analysis that aims to identify causal lipid-related risk factors for early age-related macular degeneration
790 (AMD). The studied phenotypes are ranked according to their marginal inclusion probability (MIP); four
791 likely causal traits are highlighted.



792

793 **Figure 1 - Supplementary Figure 1:** Plot illustrating the correlations between the beta values for
794 metabolites considered in our Mendelian randomisation Bayesian model averaging (MR-BMA) analysis
795 for early age-related macular degeneration (AMD). This plot visually represents the correlation matrix
796 between the genetic associations of the exposure variables with respect to their instruments. The traits
797 are labelled according to their 'Trait ID'; further information can be found in the source data.



798


799



Model 1: Free cholesterol and phospholipids in very small VLDL



Model 2: Sphingomyelins and phospholipids in very small VLDL







medRxiv preprint doi: <https://doi.org/10.1101/2022.08.24.22279172>; this version posted January 5, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).